EFEMP1 Blocking Peptide for STJ500846 peptide (STJ503995)
SPECIFICATIONS
ImmunogenSynthetic cyclic peptide corresponding to N terminal amino acids 25-42 of Human EFEMP1, peptide was covalently modified. Sequence: TYTQCTDGYEWDPVRQQC.
General Information
| Short Description | EFEMP1 Blocking Peptide for STJ500846 is synthetically produced from the 25-42 sequence and is suitable for use in western blot applications. |
| Applications | Immunodepletion/Immunocompetition |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Formulation | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction | Store at-20ยฐC for long term storage. Avoid freeze-thaw cycles. |
Target Information
| Immunogen | Synthetic cyclic peptide corresponding to N terminal amino acids 25-42 of Human EFEMP1, peptide was covalently modified. Sequence: TYTQCTDGYEWDPVRQQC. |
| Immunogen Region | 25-42 |
| Specificity | This blocking peptide is recommended for use in combination with EFEMP1 antibody, STJ500846 |
Additional Info
| Background | Binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. May play a role in cell adhesion and migration. May function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth. |
Information sourced from Uniprot.org